154 related articles for article (PubMed ID: 16247740)
1. von Willebrand disease R1374C: type 2A or 2M? A challenge to the revised classification. High frequency in the northwest of Spain (Galicia).
Penas N; Pérez-Rodríguez A; Torea JH; Lourés E; Noya MS; López-Fernández MF; Batlle J
Am J Hematol; 2005 Nov; 80(3):188-96. PubMed ID: 16247740
[TBL] [Abstract][Full Text] [Related]
2. Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function.
Flood VH; Friedman KD; Gill JC; Morateck PA; Wren JS; Scott JP; Montgomery RR
J Thromb Haemost; 2009 Nov; 7(11):1832-9. PubMed ID: 19694940
[TBL] [Abstract][Full Text] [Related]
3. Type 2M/2A von Willebrand disease: a shared phenotype between type 2M and 2A.
Seidizadeh O; Mollica L; Zambarbieri S; Baronciani L; Cairo A; Colpani P; Cozzi G; Pagliari MT; Ciavarella A; Siboni SM; Peyvandi F
Blood Adv; 2024 Apr; 8(7):1725-1736. PubMed ID: 38315875
[TBL] [Abstract][Full Text] [Related]
4. Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease.
Flood VH; Gill JC; Christopherson PA; Wren JS; Friedman KD; Haberichter SL; Hoffmann RG; Montgomery RR
J Thromb Haemost; 2012 Jul; 10(7):1425-32. PubMed ID: 22507643
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathogenesis and heterogeneity in type 3 VWD families in U.S. Zimmerman program.
Christopherson PA; Haberichter SL; Flood VH; Perry CL; Sadler BE; Bellissimo DB; Di Paola J; Montgomery RR;
J Thromb Haemost; 2022 Jul; 20(7):1576-1588. PubMed ID: 35343054
[TBL] [Abstract][Full Text] [Related]
6. Ristocetin dependent cofactor activity in von Willebrand disease diagnosis: Limitations of relying on a single measure.
Christopherson PA; Haberichter SL; Flood VH; Sicking UO; Abshire TC; Montgomery RR;
Res Pract Thromb Haemost; 2022 Oct; 6(7):e12807. PubMed ID: 36381287
[TBL] [Abstract][Full Text] [Related]
7. Critical von Willebrand factor A1 domain residues influence type VI collagen binding.
Flood VH; Gill JC; Christopherson PA; Bellissimo DB; Friedman KD; Haberichter SL; Lentz SR; Montgomery RR
J Thromb Haemost; 2012 Jul; 10(7):1417-24. PubMed ID: 22507569
[TBL] [Abstract][Full Text] [Related]
8. In vitro field study and worldwide survey assessing how clinical haemostasis laboratories analyse recombinant and plasma-derived von Willebrand factor products.
Turecek PL; Ilk R; Gritsch H
Haemophilia; 2024 Jan; 30(1):151-160. PubMed ID: 37926687
[TBL] [Abstract][Full Text] [Related]
9. Common
Flood VH; Johnsen JM; Kochelek C; Slobodianuk TL; Christopherson PA; Haberichter SL; Udani R; Bellissimo DB; Friedman KD; Montgomery RR
Res Pract Thromb Haemost; 2018 Apr; 2(2):390-398. PubMed ID: 30046743
[TBL] [Abstract][Full Text] [Related]
10. Acquired von Willebrand Disease Associated with Mantle Cell Lymphoma.
Maas D; Laros-van Gorkom B; Gianotten S; Cruijsen M; van Heerde W; Nijziel M
Case Rep Hematol; 2018; 2018():7973297. PubMed ID: 29651351
[TBL] [Abstract][Full Text] [Related]
11. The Role of the von Willebrand Factor Collagen-Binding Assay (VWF:CB) in the Diagnosis and Treatment of von Willebrand Disease (VWD) and Way Beyond: A Comprehensive 36-Year History.
Favaloro EJ
Semin Thromb Hemost; 2024 Feb; 50(1):43-80. PubMed ID: 36807283
[TBL] [Abstract][Full Text] [Related]
12. Current issues in diagnosis and treatment of von Willebrand disease.
Keesler DA; Flood VH
Res Pract Thromb Haemost; 2018 Jan; 2(1):34-41. PubMed ID: 30046704
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of von Willebrand factor concentrates by platelet adhesion to collagen using an in vitro flow assay.
Riddell A; Vinayagam S; Gomez K; Laffan M; McKinnon T
Res Pract Thromb Haemost; 2019 Jan; 3(1):126-135. PubMed ID: 30656286
[TBL] [Abstract][Full Text] [Related]
14. Combined effects of two mutations in von Willebrand disease 2M phenotype.
Woods AI; Paiva J; Kempfer AC; Primrose DM; Blanco AN; Sanchez-Luceros A; Lazzari MA
Res Pract Thromb Haemost; 2018 Jan; 2(1):162-167. PubMed ID: 30046717
[TBL] [Abstract][Full Text] [Related]
15. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD.
Flood VH; Lederman CA; Wren JS; Christopherson PA; Friedman KD; Hoffmann RG; Montgomery RR
J Thromb Haemost; 2010 Jun; 8(6):1431-3. PubMed ID: 20345715
[No Abstract] [Full Text] [Related]
16. A rat model of severe VWD by elimination of the VWF gene using CRISPR/Cas9.
Garcia J; Flood VH; Haberichter SL; Fahs SA; Mattson JG; Geurts AM; Zogg M; Weiler H; Shi Q; Montgomery RR
Res Pract Thromb Haemost; 2020 Jan; 4(1):64-71. PubMed ID: 31989086
[TBL] [Abstract][Full Text] [Related]
17. Characterization of copy-number variants in a large cohort of patients with von Willebrand disease reveals a relationship between disrupted regions and disease type.
Sadler B; Christopherson PA; Perry CL; Bellissimo DB; Haberichter SL; Haller G; Antunes L; Flood VH; Di Paola J; Montgomery RR;
Res Pract Thromb Haemost; 2023 Oct; 7(7):102232. PubMed ID: 38077814
[TBL] [Abstract][Full Text] [Related]
18. A Case of Acquired von Willebrand Disease Secondary to Myeloproliferative Neoplasm.
Sasi S; Yassin MA; Fadul AM
Case Rep Oncol; 2020; 13(2):733-737. PubMed ID: 32774267
[TBL] [Abstract][Full Text] [Related]
19. Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients.
Borràs N; Batlle J; Pérez-Rodríguez A; López-Fernández MF; Rodríguez-Trillo Á; Lourés E; Cid AR; Bonanad S; Cabrera N; Moret A; Parra R; Mingot-Castellano ME; Balda I; Altisent C; Pérez-Montes R; Fisac RM; Iruín G; Herrero S; Soto I; de Rueda B; Jiménez-Yuste V; Alonso N; Vilariño D; Arija O; Campos R; Paloma MJ; Bermejo N; Berrueco R; Mateo J; Arribalzaga K; Marco P; Palomo Á; Sarmiento L; Iñigo B; Nieto MDM; Vidal R; Martínez MP; Aguinaco R; César JM; Ferreiro M; García-Frade J; Rodríguez-Huerta AM; Cuesta J; Rodríguez-González R; García-Candel F; Cornudella R; Aguilar C; Vidal F; Corrales I
Haematologica; 2017 Dec; 102(12):2005-2014. PubMed ID: 28971901
[TBL] [Abstract][Full Text] [Related]
20. Making a diagnosis of VWD.
Branchford BR; Di Paola J
Hematology Am Soc Hematol Educ Program; 2012; 2012():161-7. PubMed ID: 23233576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
